Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
Abstract Immune checkpoint inhibitors (ICIs) have become a new hope for many patients with advanced cancer by blocking tumour immune evasion. However, with the widespread use of ICIs, immune‐related adverse events (irAEs) have also been discovered and reported increasingly. Immune‐related myocarditi...
Main Authors: | Zhijie Liu, Yiming Fan, Jun Guo, Ning Bian, Dongdong Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13912 |
Similar Items
-
Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?
by: Nechita Alexandru Cristian
Published: (2022-12-01) -
Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
by: Carlos Escobar, et al.
Published: (2022-09-01) -
Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
by: Feifei Wang, et al.
Published: (2021-07-01) -
Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis
by: Michael P. O’Shea, et al.
Published: (2023-09-01) -
Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01)